Achilles Therapeutics Analyst Ratings
Achilles Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 1005.53% | Chardan Capital | → $11 | Reiterates | Buy → Buy |
| 05/11/2023 | 1005.53% | Chardan Capital | $12 → $11 | Maintains | Buy |
| 12/07/2022 | 1608.54% | Chardan Capital | $20 → $17 | Maintains | Buy |
| 12/07/2022 | 704.02% | Piper Sandler | $10 → $8 | Maintains | Overweight |
| 04/26/2021 | 1005.53% | JP Morgan | → $11 | Initiates Coverage On | → Underweight |
| 04/26/2021 | 1910.05% | B of A Securities | → $20 | Initiates Coverage On | → Buy |
| 04/26/2021 | 2613.57% | Chardan Capital | → $27 | Initiates Coverage On | → Buy |
| 04/26/2021 | 2412.56% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 04/26/2021 | 2211.56% | Oppenheimer | → $23 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/07/2023 | 1005.53% | 查爾丹資本 | →$11 | 重申 | 購買→購買 |
| 2023年05月11日 | 1005.53% | 查爾丹資本 | $12→$11 | 維護 | 買 |
| 12/07/2022 | 1608.54% | 查爾丹資本 | $20→$17 | 維護 | 買 |
| 12/07/2022 | 704.02% | 派珀·桑德勒 | $10→$8 | 維護 | 超重 |
| 04/26/2021 | 1005.53% | 摩根大通 | →$11 | 開始承保 | →減持 |
| 04/26/2021 | 1910.05% | B of A證券 | →$20 | 開始承保 | →購買 |
| 04/26/2021 | 2613.57% | 查爾丹資本 | →$27 | 開始承保 | →購買 |
| 04/26/2021 | 2412.56% | 派珀·桑德勒 | →$25 | 開始承保 | →超重 |
| 04/26/2021 | 2211.56% | 奧本海默 | →$23 | 開始承保 | →跑贏大盤 |
What is the target price for Achilles Therapeutics (ACHL)?
阿喀琉斯療法(ACHL)的目標價格是多少？
The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1005.53% upside). 4 analyst firms have reported ratings in the last year.
查爾丹資本於2023年8月7日報道了阿喀琉斯治療公司(納斯達克：ACHL)的最新目標價。這家分析公司將目標價定為11美元，預計ACHL將在12個月內上漲至(可能上漲1005.53)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Achilles Therapeutics (ACHL)?
阿基裡斯治療公司(ACHL)的最新分析師評級是多少？
The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.
查爾丹資本提供了對阿喀琉斯治療公司(納斯達克：ACHL)的最新分析師評級，阿喀琉斯治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Achilles Therapeutics (ACHL)?
阿喀琉斯治療公司(ACHL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查看公共財務報表，與阿喀琉斯治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。阿喀琉斯治療公司的上一次評級是在2023年8月7日提交的，所以你應該預計下一次評級將在2024年8月7日左右的某個時候提供。
Is the Analyst Rating Achilles Therapeutics (ACHL) correct?
分析師對阿喀琉斯治療公司(ACHL)的評級正確嗎？
While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $1.00, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的阿喀琉斯治療(ACHL)評級被重申，目標價在0.00美元至11.00美元之間。阿喀琉斯治療公司(ACHL)目前的交易價格為1.00美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。